BACKGROUND: The metabolic phenotype that derives disproportionate energy via glycolysis in solid tumors, including glioma, leads to elevated lactate labeling in metabolic imaging using hyperpolarized [1-(13)C]pyruvate. Although the pyruvate dehydrogenase (PDH)-mediated flux from pyruvate to acetyl coenzyme A can be indirectly measured through the detection of carbon-13 ((13)C)-labeled bicarbonate, it has proven difficult to visualize (13)C-bicarbonate at high enough levels from injected [1-(13)C]pyruvate for quantitative analysis in brain. The aim of this study is to improve the detection of (13)C-labeled metabolites, in particular bicarbonate, in glioma and normal brain in vivo and to measure the metabolic response to dichloroacetate, which upregulates PDH activity. METHODS: An optimized protocol for chemical shift imaging and high concentration of hyperpolarized [1-(13)C]pyruvate were used to improve measurements of lactate and bicarbonate in C6 glioma-transplanted rat brains. Hyperpolarized [1-(13)C]pyruvate was injected before and 45 min after dichloroacetate infusion. Metabolite ratios of lactate to bicarbonate were calculated to provide improved metrics for characterizing tumor metabolism. RESULTS: Glioma and normal brain were well differentiated by lactate-to-bicarbonate ratio (P = .002, n = 5) as well as bicarbonate (P = .0002) and lactate (P = .001), and a stronger response to dichloroacetate was observed in glioma than in normal brain. CONCLUSION: Our results clearly demonstrate for the first time the feasibility of quantitatively detecting (13)C-bicarbonate in tumor-bearing rat brain in vivo, permitting the measurement of dichloroacetate-modulated changes in PDH flux. The simultaneous detection of lactate and bicarbonate provides a tool for a more comprehensive analysis of glioma metabolism and the assessment of metabolic agents as anti-brain cancer drugs.
BACKGROUND: The metabolic phenotype that derives disproportionate energy via glycolysis in solid tumors, including glioma, leads to elevated lactate labeling in metabolic imaging using hyperpolarized [1-(13)C]pyruvate. Although the pyruvate dehydrogenase (PDH)-mediated flux from pyruvate to acetyl coenzyme A can be indirectly measured through the detection of carbon-13 ((13)C)-labeled bicarbonate, it has proven difficult to visualize (13)C-bicarbonate at high enough levels from injected [1-(13)C]pyruvate for quantitative analysis in brain. The aim of this study is to improve the detection of (13)C-labeled metabolites, in particular bicarbonate, in glioma and normal brain in vivo and to measure the metabolic response to dichloroacetate, which upregulates PDH activity. METHODS: An optimized protocol for chemical shift imaging and high concentration of hyperpolarized [1-(13)C]pyruvate were used to improve measurements of lactate and bicarbonate in C6 glioma-transplanted rat brains. Hyperpolarized [1-(13)C]pyruvate was injected before and 45 min after dichloroacetate infusion. Metabolite ratios of lactate to bicarbonate were calculated to provide improved metrics for characterizing tumor metabolism. RESULTS:Glioma and normal brain were well differentiated by lactate-to-bicarbonate ratio (P = .002, n = 5) as well as bicarbonate (P = .0002) and lactate (P = .001), and a stronger response to dichloroacetate was observed in glioma than in normal brain. CONCLUSION: Our results clearly demonstrate for the first time the feasibility of quantitatively detecting (13)C-bicarbonate in tumor-bearing rat brain in vivo, permitting the measurement of dichloroacetate-modulated changes in PDH flux. The simultaneous detection of lactate and bicarbonate provides a tool for a more comprehensive analysis of glioma metabolism and the assessment of metabolic agents as anti-brain cancer drugs.
Authors: Matthew E Merritt; Crystal Harrison; A Dean Sherry; Craig R Malloy; Shawn C Burgess Journal: Proc Natl Acad Sci U S A Date: 2011-11-07 Impact factor: 11.205
Authors: Sébastien Bonnet; Stephen L Archer; Joan Allalunis-Turner; Alois Haromy; Christian Beaulieu; Richard Thompson; Christopher T Lee; Gary D Lopaschuk; Lakshmi Puttagunta; Sandra Bonnet; Gwyneth Harry; Kyoko Hashimoto; Christopher J Porter; Miguel A Andrade; Bernard Thebaud; Evangelos D Michelakis Journal: Cancer Cell Date: 2007-01 Impact factor: 31.743
Authors: Myriam M Chaumeil; Tomoko Ozawa; IlWoo Park; Kristen Scott; C David James; Sarah J Nelson; Sabrina M Ronen Journal: Neuroimage Date: 2011-07-23 Impact factor: 6.556
Authors: Tim R Eichhorn; Yuhei Takado; Najat Salameh; Andrea Capozzi; Tian Cheng; Jean-Noël Hyacinthe; Mor Mishkovsky; Christophe Roussel; Arnaud Comment Journal: Proc Natl Acad Sci U S A Date: 2013-10-21 Impact factor: 11.205
Authors: Travis C Salzillo; Jingzhe Hu; Linda Nguyen; Nicholas Whiting; Jaehyuk Lee; Joseph Weygand; Prasanta Dutta; Shivanand Pudakalakatti; Niki Zacharias Millward; Seth T Gammon; Frederick F Lang; Amy B Heimberger; Pratip K Bhattacharya Journal: Magn Reson Imaging Clin N Am Date: 2016-11 Impact factor: 2.266
Authors: E M Dunbar; B S Coats; A L Shroads; T Langaee; A Lew; J R Forder; J J Shuster; D A Wagner; P W Stacpoole Journal: Invest New Drugs Date: 2013-12-03 Impact factor: 3.850
Authors: Kelvin L Billingsley; Sonal Josan; Jae Mo Park; Sui Seng Tee; Eleanor Spielman-Sun; Ralph Hurd; Dirk Mayer; Daniel Spielman Journal: NMR Biomed Date: 2014-01-13 Impact factor: 4.044
Authors: Jae Mo Park; Daniel M Spielman; Sonal Josan; Taichang Jang; Milton Merchant; Ralph E Hurd; Dirk Mayer; Lawrence D Recht Journal: NMR Biomed Date: 2016-03-14 Impact factor: 4.044